IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.224
EU - Europa 2.286
AS - Asia 1.315
AF - Africa 379
SA - Sud America 255
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.095
IT - Italia 1.089
SG - Singapore 723
CN - Cina 456
IE - Irlanda 413
UA - Ucraina 274
CI - Costa d'Avorio 237
BR - Brasile 230
DE - Germania 158
CA - Canada 123
SN - Senegal 119
RU - Federazione Russa 111
FR - Francia 43
SE - Svezia 32
JP - Giappone 31
IN - India 28
GB - Regno Unito 23
NL - Olanda 22
BE - Belgio 21
FI - Finlandia 19
ES - Italia 18
AT - Austria 11
VN - Vietnam 11
AU - Australia 10
CH - Svizzera 10
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
IR - Iran 9
PL - Polonia 9
GR - Grecia 8
TR - Turchia 8
HU - Ungheria 7
AR - Argentina 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
ID - Indonesia 5
IQ - Iraq 5
TN - Tunisia 5
ZA - Sudafrica 5
EC - Ecuador 4
HK - Hong Kong 4
LB - Libano 4
MX - Messico 4
NG - Nigeria 4
PK - Pakistan 4
VE - Venezuela 4
BD - Bangladesh 3
BG - Bulgaria 3
KE - Kenya 3
KZ - Kazakistan 3
MA - Marocco 3
CL - Cile 2
EG - Egitto 2
GE - Georgia 2
IL - Israele 2
PE - Perù 2
RS - Serbia 2
AZ - Azerbaigian 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EU - Europa 1
IM - Isola di Man 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SL - Sierra Leone 1
UY - Uruguay 1
Totale 8.470
Salva come PNG Salva come JPEG
Città #
Santa Clara 760
Chandler 591
Houston 471
Dublin 410
Singapore 399
Chicago 323
Catania 312
Jacksonville 285
Abidjan 237
Boardman 188
Ashburn 165
Dakar 119
Nanjing 116
Cambridge 110
Andover 109
Lawrence 109
Civitanova Marche 98
Toronto 93
Bremen 60
Wilmington 57
Rome 52
Des Moines 50
San Mateo 47
Council Bluffs 46
Grafing 36
Naples 36
Shenyang 35
Nanchang 33
Saint Petersburg 32
Munich 28
Changsha 26
Jiaxing 25
Ottawa 25
Tokyo 24
Messina 23
Hebei 21
Brussels 20
Tianjin 19
Beijing 17
Pune 17
São Paulo 17
Falls Church 15
Moscow 15
San Giovanni la Punta 14
Los Angeles 13
The Dalles 13
Dong Ket 11
Helsinki 11
Milan 10
Ningbo 10
Norwalk 10
Rio de Janeiro 10
Augusta 9
Jinan 9
Madrid 9
Palermo 9
Rimini 9
Sala Baganza 9
Salerno 9
Seattle 9
Ardabil 8
Bologna 8
Lappeenranta 8
Leawood 8
New York 8
Paternò 8
San Francisco 8
Brno 7
Budapest 7
Marseille 7
Melbourne 7
Monmouth Junction 7
Paris 7
Tappahannock 7
Washington 7
Bari 6
Cagliari 6
Den Haag 6
Fukuoka 6
Gravina di Catania 6
Guangzhou 6
Lentini 6
Misterbianco 6
Pozzallo 6
San Gregorio di Catania 6
Tashkent 6
Vittoria 6
Aci Catena 5
Belo Horizonte 5
Dearborn 5
Fortaleza 5
Froges 5
Heidelberg 5
Kunming 5
Mascalucia 5
Porto Sant'Elpidio 5
Randazzo 5
Terrassa 5
Trieste 5
Villafranca Tirrena 5
Totale 6.094
Salva come PNG Salva come JPEG
Nome #
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 375
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 207
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 136
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 130
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 120
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 118
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 107
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 104
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 96
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 95
From plant to bench: natural products as source for analgesic drug development. 93
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 91
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 89
Intercellular communication and ion channels in neuropathic pain chronicization 89
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 88
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 86
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 86
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 84
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 84
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 84
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 83
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 81
Design of Small Molecules for Oncological and Neurodegenerative Diseases 80
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 80
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 78
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 78
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 77
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 76
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 76
Analgesici oppioidi: nuove opportunità nella terapia del dolore 75
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 74
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 74
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 73
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 73
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 73
Multitarget opioid ligands in pain relief: New players in an old game 72
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 72
SYNTHESIS OF (+)-(1'R,2'S) AND (1'S,2'R)-6,11-DIMETHYL-1,2,3,4,5,6-HEXAHYDRO-3-[[2'-(ALKOXYCARBONYL)-2'-PHENYLCYCLOPROPYL]METHYL]-2,6-METHANO-3-BENZAZOCIN-8-OL. COMPARISON OF THE AFFINITIES FOR SIGMA 1 AND OPIOID RECEPTORS WITHIN THE DIASTEREOISOMERIC MPCB AND CCB 71
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 70
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 70
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 70
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 70
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 69
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 69
Bivalent opioid-peptides synthesized from mu-selective monomers display preferential selectivity for delta-receptors 69
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 69
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 68
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 68
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 68
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 67
Progress in the development of more effective and safer analgesics for pain management 67
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 66
MOR/DOR targeting: an useful strategy in pain management 66
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 65
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 65
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 65
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 64
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 64
New developments in opioid receptors ligands 64
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 64
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 62
Development of new benzomorphan LP1 analogues 62
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 62
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 61
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 60
In-vitro evaluation of a new benzomorphan-based ligand 60
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 60
Modulation of opioid receptor profile of LP1 analogues through the introduction of different N-substituents 59
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 59
Specific kappa opioid receptor agonists 58
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 57
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 57
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 57
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation 56
In vitro evaluation of new benzomorphan-based ligands 56
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 56
Pain management: new long-acting opioid ligands 56
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 56
Glycopeptide- and carbohydrate-based synthetic vaccines for cancer immunotherapy 55
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 55
Idebenone: Novel strategies to improve its systemic and local efficacy 55
Synthesis of substituted pyrimidines, pyrazole[3,4-d]pyrimidines and imidazo[4,5-d]pyrimidines and evaluation of their antifungal activity 55
Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity. 53
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 53
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 52
Synthesis and pharmacological properties of N-thienyl alkylenediamines 52
INTERACTION OF A NEW ANALGESIC AGENT, LP1, WITH THE BIOMEMBRANE MODELS: CALORIMETRIC STUDY 51
Opioid multiple ligands 51
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 51
Resveratrol-loaded lipid nanocarriers: Correlation between in vitro occlusion factor and in vivo skin hydrating effect 51
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 50
Development of new benzomorphan LP1 analogues 50
The benzomorphan-based LP1 is a central-acting multitarget opioid ligand for chronic pain treatment. 49
In vitro evaluation of new benzomorphan-based ligands 49
Synthesis and structure-activity relationships of (-)-cis-N-Normetazocine-based LP1 derivatives 49
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 48
Evaluation of N-substitution in 6,7-benzomorphan compounds 48
The benzomorphan-based LP1 ligand is a suitable MOP/DOP receptors agonist for chronic pain treatment 47
Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties 47
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 46
Totale 7.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.276
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.276
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202089 0 0 0 0 0 0 0 0 0 0 59 30
2020/2021652 14 47 71 18 167 18 64 6 85 13 114 35
2021/2022934 100 105 9 24 135 11 120 34 84 26 36 250
2022/20231.774 140 97 29 239 132 267 6 344 365 35 80 40
2023/20241.092 55 138 51 40 56 262 67 111 8 30 188 86
2024/20252.929 83 520 150 227 665 426 231 137 223 264 3 0
Totale 8.799